Management 1x1 Series: James Lanthier, CEO of Mindset Pharma - The Future of Psychedelics

Grizzle Pod: Thematic Growth Investing

Innhold levert av Grizzle. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Grizzle eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

2y ago 28:32

M4A•Episoder hjem

In our second episode of the Management 1x1 Series we are thrilled to have James Lanthier, CEO of Mindset Pharma join us. Mindset is one of the world's leading companies in the field of psychedelic medicines to treat neurological and psychiatric disorders. James brings a wealth of insight to the pod and breaks down the big picture of the true disruption happening in the psychedelics industry - enjoy the interview.

Segments:

0:40 What's the opportunity set and how disruptive are psychedelics?

4:58 Where are we in terms of cultural and medical acceptance of psychedelics?

9:26 Mindset Pharma's science driven focus in the sector

13:42 Understanding the process of enhancing 1st generation psychedelic drugs.

18:45 Mindset's partnership with big pharma - Otsuka Pharmaceuticals, understanding the validation and importance for the industry.

23:40 The asset light nature of the business model.

25:13 The outlook for the psychedelics industry and what separates winners from losers?

92 episoder

#Trading #Business #Grizzle